DeepMed Research

INSTITUT CURIE

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Established: 1909-01-01

Employees: 1K

Market Cap: -

Website: http://www.curie.fr

Clinical Trials

First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)

Early Phase 1

Recruiting

Conditions: Metastatic Solid Tumor Cancer

Interventions: Combination Product: Dose escalation, first-in-human phase I clinical trial with an Expansion phase

First Posted Date: 2021-02-01

Last Posted Date: 2025-02-24

Lead Sponsor: Institut Curie

Target Recruit Count: 101

Registration Number: NCT04733027

Locations: 🇫🇷
CLCC F.Baclesse Caen, Caen, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut de Cancerologie de l'Ouest- ICO, Saint-Herblain, France

and more 1 locations

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

Not Applicable

Recruiting

Conditions: Thymoma Malignant Recurrent

Interventions: Other: Radiotherapy
Other: Surveillance after resection

First Posted Date: 2021-02-01

Last Posted Date: 2025-05-01

Lead Sponsor: Institut Curie

Target Recruit Count: 314

Registration Number: NCT04731610

Locations: 🇫🇷
Hôpital Européen Georges Pompidou, Paris, France
🇫🇷
CHU Haut Lévêque, Pessac, France
🇫🇷
CHU Caen, Caen, France

and more 17 locations

Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)

Not Applicable

Completed

Conditions: Uveal Melanoma

Interventions: Other: Supportive care visit with questionnaires
Other: Oncological standard visit

First Posted Date: 2021-01-28

Last Posted Date: 2025-02-06

Lead Sponsor: Institut Curie

Target Recruit Count: 162

Registration Number: NCT04728113

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷
Institut Curie, Paris, France

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Metastatic Breast Cancer

Interventions: Biological: Chemotherapy monitoring by circulating tumor DNA analysis

First Posted Date: 2021-01-22

Last Posted Date: 2024-06-10

Lead Sponsor: Institut Curie

Target Recruit Count: 214

Registration Number: NCT04720729

Locations: 🇫🇷
Institut Curie, Paris, France

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Phase 2

Recruiting

Conditions: Retinoblastoma

Interventions: Drug: Melphalan or Melphalan + Topotecan
Drug: etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
Drug: Carboplatin administered on Day 1
Device: Cryotherapy (local treatment)
Device: Thermotherapy (local treatment)
Device: Iodine-125 plaques (local treatment)
Drug: Intravitreal Melphalan chemotherapy injections (local treatment)

First Posted Date: 2020-12-23

Last Posted Date: 2024-01-12

Lead Sponsor: Institut Curie

Target Recruit Count: 225

Registration Number: NCT04681417

Locations: 🇫🇷
Bordeaux Chu, Bordeaux, France
🇫🇷
MONTPELLIER CHU Hopital Arnaud De Villeneuve, Montpellier, France
🇫🇷
Strasbourg Chu, Strasbourg, France

and more 25 locations

DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI)

Not Applicable

Recruiting

Conditions: Cancer Patients With Cancer Pain

Interventions: Other: Experimental group
Other: standrad group

First Posted Date: 2020-11-18

Last Posted Date: 2024-01-29

Lead Sponsor: Institut Curie

Target Recruit Count: 270

Registration Number: NCT04634097

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest Paul Papin, Angers, France
🇫🇷
Institut Curie, Saint-cloud, France
🇫🇷
GH Diaconesses Croix Saint Simon (GHDCSS), Paris, France

and more 1 locations

The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)

Not Applicable

Active, not recruiting

Conditions: Cancer, Advanced

Interventions: Other: Hospital day care follow-up

First Posted Date: 2020-10-27

Last Posted Date: 2024-02-16

Lead Sponsor: Institut Curie

Target Recruit Count: 144

Registration Number: NCT04604873

Locations: 🇫🇷
Institut de Cancerologie de L'Ouest, Saint-herblain, France
🇫🇷
Institutcurie Paris, Paris, France
🇫🇷
Institut Bergonie, Bordeaux, France

and more 3 locations

Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.

Not Applicable

Completed

Conditions: Surgery
Breast Cancer

Interventions: Diagnostic Test: Sorbstar®
Diagnostic Test: Dog Detection

First Posted Date: 2020-09-09

Last Posted Date: 2022-02-03

Lead Sponsor: Institut Curie

Target Recruit Count: 35

Registration Number: NCT04541537

Locations: 🇫🇷
Institut Curie, Paris, France

Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology

Not Applicable

Completed

Conditions: Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma)
Colorectal With Associated Risk Factors

Interventions: Other: multidisciplinary assessment and intervention

First Posted Date: 2020-07-20

Last Posted Date: 2022-11-17

Lead Sponsor: Institut Curie

Target Recruit Count: 30

Registration Number: NCT04478175

Locations: 🇫🇷
Institut Curie, Paris, France

Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer
Surgery

Interventions: Other: Coaching sessions

First Posted Date: 2020-07-13

Last Posted Date: 2024-04-09

Lead Sponsor: Institut Curie

Target Recruit Count: 69

Registration Number: NCT04469205

Locations: 🇫🇷
Institut Curie, Saint-Cloud, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy